NCT03781219 2023-05-31A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 MutationShanghai Kechow Pharma, Inc.Phase 1 Unknown45 enrolled
NCT05019534 2022-05-19Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal CancerWest China HospitalPhase 1 Unknown12 enrolled